@article{9eb5f0e57dae41e399d269655fa97f53,
title = "Imatinib and pegylated IFN-alpha 2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response",
keywords = "chronic myeloid leukemia, interferon, immune system, tyrosine kinase inhibitor, therapy discontinuation, NATURAL-KILLER-CELLS, CHRONIC MYELOGENOUS LEUKEMIA, CD8(+) T-CELLS, CML PATIENTS, MESYLATE DISCONTINUATION, INTERFERON-ALPHA, NK-CELLS, REMISSION, THERAPY, DASATINIB, 3121 General medicine, internal medicine and other clinical medicine",
author = "Perttu Koskenvesa and Anna Kreutzman and Peter Rohon and Markus Pihlman and Emmi Vakkila and Anu Rasanen and Mirja Vapaatalo and Kari Remes and Tuija Lundan and Henrik Hjorth-Hansen and Jukka Vakkila and Bengt Simonsson and Satu Mustjoki and Kimmo Porkka",
year = "2014",
month = may,
doi = "10.1111/ejh.12258",
language = "English",
volume = "92",
pages = "413--420",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley",
number = "5",
}